Objective: It is known that the immune system is frequently affected in patients with head and neck cancer. Although immune dysfunction could be multifactorial, this immune system may be modulated by specific nutritional substrates, such as arginine. The aim of our study was to evaluate the effect of enteral nutrition supplemented with arginine on c-reactive protein (CRP), interleukin 6 (IL-6) and tumour necrosis factor (TNFa) in surgical head and neck cancer patients. Design: Randomized trial. Setting: Tertiary care. Subjects: A population of 36 patients with oral and laryngeal cancer were enrolled. Interventions: At surgery patients were randomly allocated to two groups: (a) patients receiving an enteral diet supplements with arginine and dietary fibre (group I, n ¼ 18); (b) patients receiving an isocaloric, isonitrogenous enteral formula (group II, n ¼ 18). Perioperatively and on postoperative day 5 the following parameters were evaluated: serum values of prealbumin, transferrin, albumin, total number of lymphocytes, interleukin 6, tumour necrosis factor a and c-reactive protein.
Introduction
It is known that the immune system is frequently affected in patients with head and neck cancer. Surgery and malnutrition (which is frequent in these patients) have also been found to depress the immune system (Van Bokhorst-de van der Schueren et al, 1998) . The alterations in the host defence mechanism make patients susceptible to the above-mentioned complications. Although immune dysfunction is multifactorial, the immune system may be modulated by specific nutritional substrates, such as arginine (Daly et al, 1988) . Supplementation with arginine improved wound healing and enhanced immune function in animals by decreasing the T cell dysfunction associated with injury . Other studies have shown that arginine increased lymphocytic interleukin-2 production and augmented lysis of tumours by macrophages . There is evidence suggesting that enteral nutrition, supplemented with different agents including arginine and dietary fibre, improves immune function and reduces postoperative complications, in different groups of patients such as pancreatic surgery , surgery of stomach and colo-rectum cancer (Gianoti et al, 1999; Wu et al, 2001) , critically ill patients (Caparros et al, 2001 ) and head and neck cancer patients (Van Bokhorst-de van der Schueren et al, 2001) .
The aim of our study was to evaluate the effect of enteral nutrition supplemented with arginine on c-reactive protein (CRP), interleukin 6 (IL-6) and tumour necrosis factor (TNFa) in surgical head and neck cancer patients.
Material and methods

Patients
A population of 36 patients with a previous weight loss of 5 -10% (6 months) and oral or laryngeal cancer was enrolled. Exclusion criteria included severely impaired hepatic functon (total bilirubin concentration > 3.5 mg=dl) and renal function (serum creatinine concentration > 2.5 mg=dl), ongoing infections, autoimmune disorders, steroids treatment and well-nourished (weight loss < 10% of body weight). The study was a prospective concealed randomized trial carried out from March 1999 to January 2001. The study was blinded (patients and investigator). Baseline studies on all patients consisted of complete history taking and physical examination. General assessment of nutritional status included measurements of height, body weight, body mass index (BMI; kg=m 2 ). Informed consent was provided by patients.
Nutrition
At surgery patients were randomly allocated (sealed envelopes) to two groups: (a) patients receiving an enteral diet supplements with arginine (group I, n ¼ 18); (b) patients receiving an isoenergetic, isonitrogenous enteral formula (group II, n ¼ 18). Table 1 shows the composition of the two enteral diets. Enteral feeding was started within 24 h of surgery at a rate of 20 ml=h, via an intraoperatively placed nasogastric tube. The infusion rate was progressively increased every 24 h until the daily nutritional goal (32 total kcal=kg; 1.7 g protein=kg) was reached, on postoperative day 4. All patients reached 100% of calculated requirements. Group I received a daily dose of argine of 12.5 g during an average of 20 days. Prophylactic antibiotic treatment was given for 3 days postoperatively (ceftazidime, 500 mg three times daily i.v. and clyndamicine 300 mg three times daily i.v.).
Patient monitoring
Perioperatively and on postoperative day 5 the following parameters were evaluated: serum values of prealbumin (mg=dl), transferrin (mg=dl), albumin (g=dl), total number of lymphocytes (10 6 =ml), IL-6 (pg=ml), a TNFa (pg=ml) and CRP (mg=dl).
Assays
Fasting blood samples were drawn for measurement of albumin (3.5 -4.5 g=dl), prealbumin (18 -28 mg=dl), transferrin (250 -350 mg=dl), and lymphocytes (1.2 -3.5Â10 6 =ml) with an autoanalyser (Hitachi, ATM, Mannheim, Germany).
Interleukins were measured by immulite analyser (DPC, Los Angeles, CA, USA). A 100 ml aliquot of serum (heparinized plasma) was required to determine IL-6 and TNFa; analytical sensivity of IL-6 and TNFa was 5 and 1.7 pg=ml, respectively. CRP was measured by immunoturbimetry (Roche Diagnostcis GmbH, Mannheim, Germany); analytical sensivity 0.5 mg=dl. Samples were assayed in duplicate in one day by the same investigator to avoid inter-investigator variability.
Statistical analysis
The results were expressed as average AE standard deviation. The distribution of variables was analysed using the Kolmogorov -Smirnov test. Quantitative variables with normal distribution were analysed with two-tailed paired or unpaired Student's t-test, as needed and analysis of variance (ANOVA). Non-parametric variables were analysed with the Friedman -Wilcoxon tests. To minimize the potential for introducing bias, all randomized patients were included in the comparisons, irrespective of whether or not and for how long they complied with their allocated regimen (intentionto-treat analysis). A P-value under 0.05 was considered statistically significant.
Results
Thirty-six patients were enrolled in the study. The mean age was 59.6 AE 10.9 y (two females=34 males). There were 18 patients in the group I (supplemented diet) and 18 patients in the control diet group. Characteristics of the patients on Effect of CRP and interleukins blood levels DA de Luis et al enrollment were similar for the two groups, reflecting the homogeneity of the patients. There were no significant differences with regard to gender, mean age, body weight, location and stage of tumour (Table 2 ). Six patients underwent resection of a tumour located in the oral cavity with unilateral or bilateral neck disection; 30 patients underwent laryngectomy (total or partial) or pharyngo-laryngectomy, with the same distributions of surgery in group I and II. Duration of enteral nutrition in both groups was similar with an average duration of 9.6 AE 9 days. As shown in Table 3 , no significant intergroup differences in the trend of the three plasma proteins and weight were detected.
CRP decreased in both groups (group I: 152.9 AE 76.9 vs 68.9 AE 82.5 mg=dl; P < 0.05; and group II: 105.9 AE 92 vs 43.6 AE 59.1 mg=dl; P < 0.05). IL-6 did not change (group I: 16.3 AE 12.3 vs 35.6 AE 83.4 pg=ml; NS; and group II: 22.8 AE 40 vs 9.9 AE 17.7 pg=ml; NS). TNFa did not show any changes (group I: 4.6 AE 1.6 vs 5.1 AE 1.5 pg=ml; NS; and group II: 8.8 AE 6.1 vs 5.8 AE 1.7 pg=ml; NS). Lymphocytes increased in both groups (group I: 1405.6 AE 517 vs 1634 AE 529Â10 6 =ml; P < 0.05; and group II: 1355 AE 696 vs 1561 AE 541Â10 6 =ml; P < 0.05).
Discussion
Malnutrition and immunosuppression are two characteristics of head and neck cancer patients (Riboli et al, 1996; Bassett & Dobie, 1983) . Malnutrition is due to reduced dietary intake secondary to dysphagia, and interleukins secreted by tumour with catabolic action play a dominant role (Todorov et al, 1996) . Immunosuppression is related to surgery and immunosuppressive capacity of the tumour (Katz, 1983) .
There is evidence suggesting that enteral nutrition, supplemented with immunomodulatory agents including arginine, improve immune function and reduce postoperative complications, in different groups of patients such as pancreatic surgery , surgery of stomach and colo-rectum cancer (Gianoti et al, 1999; Wu et al, 2001) , critically ill patients (Caparros et al, 2001) , and head and neck cancer patients (Riso et al, 2000; Van Bokhorst-de van der Schueren et al, 2001) .
Certain nutrients such as the semi-essential amino acid arginine, RNA and omega 3 fatty acids, may act pharmacologically on the immune system. It has been suggested that these nutrients may improve host immune defences, and specific nutrient substrates seem to act through different mechanisms, although these formulas combine other immunomodulating nutrients and it is difficult to discern what the treatment effect of arginine alone is (Van Bokhorstde van der Schueren et al, 1998; Gianoti et al, 1999; Senkal et al, 1995) .
In our study with an arginine supplemented formula the changes in IL-6 and TNFa were similar in both groups without statistical difference. CRP decreased in both groups and lymphocyte counts increased. Schilling et al (1996) did not find significant differences in phagocytic activity of monocytes, activated surface antigen HLA-DR, and CRP levels between a control formula and a formula supplemented with arginine, omega 3 fatty acids and nucleotides; however both formulas were better than a low energy=low fat intravenous solution. However, Taylor et al (1999) showed a decrease in CRP levels in head injury patients treated with an enhanced formula without differences in other biochemical parameters. These results were confirmed by Weimann et al (1998) in a group of multiple organ failure patients. Perhaps the differences among studies could be due to different treatment of patients and different nutrients in enhanced formulas. It is clear that enteral nutrition is a good option to attenuate the immunosuppression status of these patients (Tagaki et al, 2000; Windsor et al, 1998; Lin et al, 1997) , with better results than parenteral nutrition. Arginine stimulates anabolic hormone release, improves survival in gut-derived sepsis by modulating bacterial clearance and accelerates wound healing (Reynolds et al, 1988) . Fibre-supplemented enteral formulas may have a beneficial effect on components of the gut barrier, as well as the gut mucosa, and on bacterial translocation (Cummings et al, 1983) . Insoluble fibre, rich in cellulose and lignin, can exert beneficial effects by increasing faecal mass through Effect of CRP and interleukins blood levels DA de Luis et al water absorption, thereby regulating the intestinal transit. Soluble fibres are degraded by anaerobic colonic flora forming short-chain fatty acids, with a trophic effect on the mucosa of the large bowel.
In conclusion, enhanced-formula did not change IL-6 and TNFa levels. Further studies are needed to determine whether route of nutrition or type of formula is the key in why the enhanced-formula failed to show a beneficial effect on IL-6 and TNFa.
